Dr. Gaweco is the President and CEO of Innovimmune Biotherapeutics, Inc. Prior to founding the company in 2010, he was Global Clinical Science Leader at Roche and Early Clinical Leader at Pfizer responsible for the worldwide clinical development of small molecule and biologic NME candidates from Lead Discovery through Clinical Development & Commercialization in the Autoimmune Disease, Inflammation, Immunology and Virology therapeutic areas. Previously, he was Senior Medical Scientist, Medical Affairs at AstraZeneca having worked with the launch products Nexium & Crestor. His successful track-record in Global Drug Development includes leadership roles in advancing several NMEs against novel therapeutic targets: Xeljanz [CP-690,550] (JAK3 Inhibitor; 2003 Science), retinoic acid receptor-related orphan receptor [ROR] & T helper 17 [Th17] cell modulators, Nuclear hormone receptors, Integrin antagonists, macrophage migration inhibitory factor [MIF] inhibitors, anti-CD20, anti-CD25/anti-IL-2R, Pegasys and Prograf. Dr. Gaweco served as member of the Clinical Research Advisory Council (2003-2008) and Training & Workforce (2004-2007) Committees of the American Society of Transplantation. Before joining the industry, Dr. Gaweco held dual faculty appointments as Assistant Professor of Medicine at the Division of Gastroenterology & Hepatology, Department of Medicine & Assistant Professor of Pathology at the Department of Pathology at Loyola University Medical Center in Chicago. Dr. Gaweco received his M.D. and Ph.D. magna cum laude in Immunology and was trained in Pathology at the Ruprecht-Karls-Universität Heidelberg, Germany. He has completed management trainings in Executive Leadership Development at London Business School and Biomedical Research at Harvard School of Public Health. He was a recipient of the United Kingdom's ORS Awards scholarship for the University of Oxford (Oriel College & Nuffield Department of Surgery) and numerous Young Investigator & Scientist Awards from international professional medical societies for his academic research in Inflammation and Immunomodulation. Dr. Gaweco has authored over 100+ peer-reviewed journal articles (including Science), book chapters, abstracts and conference proceedings; and inventor of 20+ worldwide patent filings in immunomodulatory drugs for Autoimmune and ImmunoInflammation Diseases. He served as Visiting Professor at SUNY Downstate Medical Center (2012-2016) and is currently a Guest Faculty (2012-present) at the Georgetown University Biotechnology Program & Adjunct Professor at Georgetown University Medical Center, Georgetown University School of Medicine.